2020 Preprint
Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donors
Abstract: 42 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a rapidly 43 unfolding pandemic, overwhelming health care systems worldwide 1 . Clinical manifestations of 44 Coronavirus-disease 2019 (COVID-19) vary broadly, ranging from asymptomatic infection to 45 acute respiratory failure and death 2 , yet the underlying mechanisms for this high variability are 46 still unknown. Similarly, the role of host immune responses in viral clearance of COVID-19 47 remains unresolved. For SARS-CoV (2002/03…
View published versions
Search citation statements
Paper Sections
Select...
139
67
45
11
Citation Types
33
240
1
15
Year Published
2020
2025
Publication Types
Select...
134
88
5
2
Relationship
4
225
Authors
Journals
Cited by 226 publications
(289 citation statements)
References 37 publications
33
240
1
15
“…If we consider samples with a SI > 3 as responders, we identified 2 out of 10 HC (20%) to have these cross-reactive T-cells. This is in good accordance with a recent report on the presence of virus-specific CD4 + T-cells in COVID-19 patients, which reported the presence of SARS-CoV-2-reactive T-cells in 34% of the HC (Braun et al, 2020). The role of pre-existing SARS-CoV-2-reactive T-cells as a correlate of protection or pathology is unclear, and needs to be addressed in prospective studies.…”
Section: Resultssupporting
confidence: 93%
“…If we consider samples with a SI > 3 as responders, we identified 2 out of 10 HC (20%) to have these cross-reactive T-cells. This is in good accordance with a recent report on the presence of virus-specific CD4 + T-cells in COVID-19 patients, which reported the presence of SARS-CoV-2-reactive T-cells in 34% of the HC (Braun et al, 2020). The role of pre-existing SARS-CoV-2-reactive T-cells as a correlate of protection or pathology is unclear, and needs to be addressed in prospective studies.…”
Section: Resultssupporting
confidence: 93%
“…Indeed cross-reactive TCRs predicted to target epitopes not unique to SARS-CoV-2 start at a higher level, and only seem to gradually increase as the infection progresses. This may be in line with prior reports of existing cross-reactive T cells in uninfected patients (9, 11, 32).…”
Section: Resultssupporting
confidence: 92%
“…4A,B). When taken in aggregate, our results are largely consistent with previous ORF-level analyses using peptide pools (7, 8, 15-17) . However, our approach provided an increased level of granularity that enabled us to identify specific epitope sequences and highlighted allele-specific differences.…”
Section: Resultssupporting
confidence: 90%
